Brivaracetam for Alzheimer's Disease
(EHAD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests brivaracetam to determine if it can help individuals with mild cognitive impairment (MCI) or Alzheimer's disease (AD) who exhibit unusual brain activity, such as epileptic activity. Researchers aim to discover whether brivaracetam can reduce this unusual brain activity and improve cognitive function. The trial is open to those diagnosed with MCI or AD who show signs of epileptic brain activity, as identified in specific brain scans. Participants will undergo careful monitoring with brain scans while taking the medication in a hospital setting, followed by continued use at home. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
You may need to stop taking certain medications, especially if they affect the central nervous system (like benzodiazepines or narcotics) or are antiseizure medications. However, you can continue taking cholinesterase inhibitors and memantine if your dosage has been stable for at least 30 days before joining the study.
Is there any evidence suggesting that brivaracetam is likely to be safe for humans?
Earlier studies found that brivaracetam was generally well-tolerated, with most people experiencing mild to moderate side effects. Research shows that few people stopped taking it due to side effects, suggesting that brivaracetam is relatively safe for humans. However, everyone can react differently to a treatment.12345
Why do researchers think this study treatment might be promising?
Unlike the standard Alzheimer's treatments, which mainly focus on reducing symptoms or slowing disease progression, brivaracetam targets brain activity directly. Researchers are excited about brivaracetam because it is typically used to control seizures and may reduce abnormal brain activity linked to Alzheimer's. This potential new mechanism of action could offer a novel way to address cognitive decline by reducing epileptic events and high-frequency oscillations, which are thought to play a role in Alzheimer's disease.
What evidence suggests that brivaracetam might be an effective treatment for Alzheimer's disease?
Research has shown that brivaracetam, the investigational treatment in this trial, may help treat Alzheimer's disease by reducing seizure-related brain activity. In studies with mice that have Alzheimer's, brivaracetam lowered unusual brain activity and improved memory. It works by affecting a protein in the brain to calm nerve activity. Some research suggests it might cause temporary memory problems, but results vary. Overall, early research suggests brivaracetam could help manage brain activity in people with Alzheimer's.46789
Who Is on the Research Team?
Keith A Vossel, MD, MSc
Principal Investigator
Mary S. Easton Center at UCLA
Are You a Good Fit for This Trial?
This trial is for adults aged 45-70 with mild cognitive impairment or Alzheimer's, showing specific epileptic activity on EEG. Participants need a reliable informant and must meet certain criteria including scoring above 18 on the Mini-Mental State Exam. Those with other risk factors for epilepsy, using antiseizure meds, significant brain lesions or systemic illnesses, or affecting CNS medications can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-surgical Assessment
Participants undergo MRV, MRA, gadolinium-enhanced MRI, and cognitive testing prior to electrode implantation
Surgical and Initial Treatment
Hippocampal depth electrodes are implanted, and brivaracetam is administered intravenously to assess its effects on epileptic activity
Long-term Treatment
Participants take brivaracetam orally for 1 year with follow-up visits for cognitive testing and biomarker analysis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Brivaracetam
Trial Overview
The study aims to understand hippocampal activity in Alzheimer's patients with suspected epilepsy and test if Brivaracetam can reduce this abnormal activity and improve cognition. It involves monitoring through depth electrode and scalp EEG in an open-label pilot setup where all participants receive the drug.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
25 subjects with MCI or AD who meet inclusion criteria will receive the drug: brivaracetam. A scalp EEG will record their brain activity for 6 days at the hospital. On nights 4 and 5, we will intravenously administer brivaracetam. Doses will vary depending on their effects on epileptic activity. We will determine whether brivaracetam 25 mg IV suppresses the number of epileptic events and pHFOs by \>50%, which is analogous to our preclinical investigations with this drug in AD models. If the 50% suppression is reached, the same dosage will be repeated the following night to ensure reproducibility. If the 50% suppression is not reached, then the dosage of brivaracetam will be increased to 50 mg the following night. Once the depth electrode is surgically removed, subjects will go home with a supply of brivaracetam. They will take the drug for 12 months.
Brivaracetam is already approved in European Union, United States, Canada for the following indications:
- Partial-onset seizures with or without secondary generalisation
- Focal (partial) onset seizures in epilepsy patients 1 month of age and older
- Partial-onset seizures with or without secondary generalisation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Citations
Antiseizure Medications in Alzheimer's Disease from ...
Brivaracetam (BRV; 8.5 mg/kg/day), an AMS closely related to LEV, and ethosuximide (30 mg/mL) reduced spike-wave discharges (SWDs) detected in ...
Brivaracetam, but not ethosuximide, reverses memory ...
Ethosuximide and brivaracetam reduce spike-wave discharges in transgenic Alzheimer's disease mice. Transgenic Alzheimer's disease (AD) mice ...
Anti-epileptogenic effects of synaptic vesicle protein 2A ...
Brivaracetam treatment displayed marked anti-epileptogenic effects in both aged and young Tg2576 mice, including when treatment is ceased prior to initiating ...
The impact of brivaracetam on cognitive processes and ...
BRV may cause transient memory deficits as well as anxiety disturbances. However, the results are varied and depend on the type of memory, used dose, and ...
The Effect of Co-Administration of Levetiracetam or ...
Preclinical studies indicate that levetiracetam and brivaracetam have beneficial effects in mouse models of Alzheimer's disease [16,17,18]. Furthermore, ...
The impact of brivaracetam on cognitive processes and ...
In preclinical studies, the BRV has been evaluated for the treatment of migraine [9], neuropathic pain [10], and Alzheimer's disease [11].
Safety & Tolerability | BRIVIACT® (brivaracetam) CV
Safety Data · Most adverse events (AEs) were reported to be mild or moderate · Across all 3 trials, low discontinuation rates due to adverse events were observed ...
Briviact (brivaracetam) dosing, indications, interactions, ...
Use Caution/Monitor. Brivaracetam plasma concentration decreased by 21%. brivaracetam increases levels of phenytoin by decreasing metabolism. Use Caution/ ...
Brivaracetam: Uses, Interactions, Mechanism of Action
View sample adverse effects data in our new Data Library! See the data ... Alzheimer's Disease (AD) / Mild Cognitive Impairment (MCI) · 1, somestatus, stop ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.